Chugai Pharmaceutical Co., Ltd.
Notice Regarding Revision of Stock Compensation Plan
Chugai Pharmaceutical will abolish the restricted stock compensation plan and introduce a trust-based stock compensation plan. Implementation is planned upon approval at the shareholders meeting on March 26, 2026.
Key Figures
- Scheduled Shareholders Meeting Date: 2026-03-26 (115th Annual General Meeting)
- Plan Participants: Directors, Executive Officers, Employees of the Company and Directors and Employees of Subsidiaries
- New Plan Names: BIP Trust (for Executives), ESOP Trust (for Employees)
AI要約
Overview of Stock Compensation Plan Revision
Chugai Pharmaceutical Co., Ltd. has resolved to abolish the restricted stock compensation plan targeted at directors (excluding directors not engaged in business execution), executive officers, and employees, and to introduce a trust-based stock compensation plan. The same revision will be applied to directors and employees of subsidiaries, contingent on approval at the shareholders meeting scheduled for March 2026. The new plan will adopt two mechanisms: a BIP Trust for executives and an ESOP Trust for employees, aiming to enhance awareness of contributing to medium- to long-term corporate value growth.
Outlook and Impact on Shareholders
With the introduction of this plan, the existing restricted stock compensation plan will be abolished and no new restricted stock allocations will be made; however, already granted shares will continue to exist. Upon expiration of the trust period, new trusts will be established and existing trusts modified or supplemented to maintain continuous operation of the plan. A remuneration committee has been established to ensure transparency, and since implementation will occur following shareholders meeting approval, the impact on shareholders is expected to contribute positively to enhancing transparency and medium- to long-term corporate value.
